These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12522928)

  • 1. [Antibacterial activity of imipenem/cilastatin (thienam) against agents causing pyoseptic processes].
    Vasina TA; Kartavenko VI; Men'shikova ED; Shabanov AK; Mironov AV
    Khirurgiia (Mosk); 2002; (12):45-7. PubMed ID: 12522928
    [No Abstract]   [Full Text] [Related]  

  • 2. Susceptibility of bacterial isolates from complicated skin and skin structure infections to cefazolin, imipenem-cilastatin, ciprofloxacin and ofloxacin.
    Liu HH; Bolash NK; McAnany ME; Lynch RA
    Drugs; 1995; 49 Suppl 2():215-8. PubMed ID: 8549308
    [No Abstract]   [Full Text] [Related]  

  • 3. [A trial of the clinical use of thienam in treating severe and life-threatening suppurative-septic complications].
    Grinev MV; Shapot IuB; Tsibin IuN; Gal'tseva IV; Chiritso BG
    Vestn Khir Im I I Grek; 1996; 155(4):54-6. PubMed ID: 8992722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Revaluation of current antimicrobials. Series 24: imipenem/cilastatin].
    Kohno S; Wada K
    Jpn J Antibiot; 1994 Dec; 47(12):1629-36. PubMed ID: 7877247
    [No Abstract]   [Full Text] [Related]  

  • 5. Imipenem/cilastatin as empirical treatment of severe infections in compromised patients.
    Biglino A; Bonasso M; Gioannini P
    J Chemother; 1991 Jan; 3 Suppl 1():208-12. PubMed ID: 12041767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imipenem with cilastatin; indications and contraindications].
    Loebis LH
    Ned Tijdschr Geneeskd; 1992 Mar; 136(13):613-6. PubMed ID: 1557157
    [No Abstract]   [Full Text] [Related]  

  • 7. Imipenem-cilastatin in the treatment of hospital infections.
    Mao P; Enrichens F; Olivero G; Sciascia C; Benedetto G; Franchello A; Olivero S
    J Chemother; 1991 Jan; 3 Suppl 1():205-7. PubMed ID: 12041766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of experimental splenic autotransplantation and imipenem-cilastatin treatment in postsplenectomy Pseudomonas aeruginosa sepsis.
    Eskitürk A; Söyletir G; Peker O; Haklar G; Yalçin AS; Demirel M; Işgör A
    Res Exp Med (Berl); 1995; 195(3):163-9. PubMed ID: 8570911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of acquired immunity in mice by imipenem/cilastatin.
    Ortega E; de Pablo MA; Gallego AM; Gaforio JJ; Alvarez C; Ruiz-Bravo A; de Cienfuegos GA
    J Antimicrob Chemother; 1999 Oct; 44(4):561-4. PubMed ID: 10588322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of natural immunity in mice by imipenem/cilastatin.
    Ortega E; de Pablo MA; Gallego AM; Alvarez C; Pancorbo PL; Ruiz-Bravo A; de Cienfuegos GA
    J Antibiot (Tokyo); 1997 Jun; 50(6):502-8. PubMed ID: 9268007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats.
    Nakamura T; Hashimoto Y; Kokuryo T; Inui KI
    Pharm Res; 1998 May; 15(5):734-8. PubMed ID: 9619782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses.
    Orsini JA; Moate PJ; Boston RC; Norman T; Engiles J; Benson CE; Poppenga R
    J Vet Pharmacol Ther; 2005 Aug; 28(4):355-61. PubMed ID: 16050815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in clinically separated strains of glucose non-fermented gram-negative bacilli following the induction of imipenem/cilastatin.
    Fujita J; Negayama K; Higuchi K; Nakano M; Yamaji Y; Irino S
    J Intern Med; 1991 Jun; 229(6):558-9. PubMed ID: 2045767
    [No Abstract]   [Full Text] [Related]  

  • 14. [Experience in the use of imipenem/cilastatin (thienam) in a surgical clinic].
    Briskin BS; Khachatrian NN; Nekrasova NI; Kuznetsov EV; Suplotova AA; Sosnovikova OG
    Khirurgiia (Mosk); 2000; (9):56-61. PubMed ID: 11026205
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of imipenem-resistant Pseudomonas aeruginosa strains from cystic fibrosis patients.
    Godard C; Leroy J; Michel-Briand Y
    J Antimicrob Chemother; 1992 Nov; 30(5):721-4. PubMed ID: 1493989
    [No Abstract]   [Full Text] [Related]  

  • 16. Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus.
    Oka S; Goto M; Kaji Y; Kimura S; Matsuda K; Asahi Y; Sanada M; Nakagawa S; Inoue M; Shimada K
    J Antimicrob Chemother; 1993 Apr; 31(4):533-41. PubMed ID: 8514648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
    Babinchak T; Ellis-Grosse E; Dartois N; Rose GM; Loh E; ;
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S354-67. PubMed ID: 16080073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections.
    Garbino J; Villiger P; Caviezel A; Matulionyte R; Uckay I; Morel P; Lew D
    Infection; 2007 Jun; 35(3):161-6. PubMed ID: 17565457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of beta-lactam antibiotics imipenem/cilastatin and cefodizime on cellular and humoral immune responses in BALB/c-mice.
    Grochla I; Ko HL; Beuth J; Roszkowski K; Roszkowski W; Pulverer G
    Zentralbl Bakteriol; 1990 Nov; 274(2):250-8. PubMed ID: 2085374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Selective intra-arterial use of small doses of thienam and vasaprostanin the treatment of suppurative diseases of the foot in patients with diabetes mellitus].
    Antsypovich EA; Molchanov VF; Kadyshev IuG; Brusnitsyna MA
    Vestn Khir Im I I Grek; 1998; 157(1):76-7. PubMed ID: 9611324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.